CLINICAL UTILITY OF THE REALTIME HCV ASSAY (ABBOTT MOLECULAR) FOR RESPONSE-GUIDED THERAPY IN PATIENTS INFECTED WITH HCV GENOTYPES 1, 2, OR 3 AND TREATED WITH PEGINTERFERON-ALFA PLUS RIBAVIRIN (PEGIFN/RBV)

被引：0
|
作者：
Vermehren, Johannes [1 ]
Yu, Ming-Lung [2 ]
Monto, Alexander [3 ]
Yao, Joseph D. [4 ]
Anderson, Christopher [5 ]
Bertuzis, Rasa [5 ]
Schneider, George [5 ]
Sarrazin, Christoph [1 ]
机构：
[1] Klinikum JW Goethe Univ, Med Klin 1, Frankfurt, Germany
[2] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[3] San Francisco VA Med Ctr, San Francisco, CA USA
[4] Mayo Med Labs, Rochester, MN USA
[5] Abbott Mol, Des Plaines, IL USA
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
972
引用
收藏
页码：789A / 790A
页数：2
相关论文
共 50 条
  • [1] RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1
    Manns, M. P.
    Poordad, F.
    Bacon, B. R.
    Bruno, S.
    Esteban, R.
    Silva, M.
    Buti, M.
    Burroughs, M.
    Sniukiene, V.
    Boparai, N.
    Brass, C. A.
    Albrecht, J. K.
    Bronowicki, J. -P.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S182 - S183
  • [2] Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Reduces Treatment Duration in NaiVE and Peginterferon Alfa-2B/Ribavirin Previous-Treatment-Failure Patients With HCV Genotype 1
    Manns, Michael P.
    Poordad, Fred
    Bacon, Bruce R.
    Bruno, Savino
    Esteban, Rafael
    Silva, Marcelo O.
    Buti, Maria
    Burroughs, Margaret
    Sniukiene, Vilma
    Boparai, Navdeep
    Brass, Cliflord A.
    Albrecht, Janice K.
    Bronowicki, Jean-Pierre
    GASTROENTEROLOGY, 2011, 140 (05) : S942 - S942
  • [3] SAFETY BENEFITS OF RESPONSE-GUIDED THERAPY WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR) IN PREVIOUSLY UNTREATED PATIENTS WITH HCV GENOTYPE 1 INFECTION
    Manns, Michael P.
    McCone, Jonathan
    Davis, Mitchell
    Shiffman, Mitchell L.
    Rossaro, Lorenzo
    Bourliere, Marc
    Pedicone, Lisa
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Bruno, Savino
    HEPATOLOGY, 2011, 54 : 813A - 813A
  • [4] Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test
    Kanda, T.
    Imazeki, F.
    Yonemitsu, Y.
    Mikami, S.
    Takada, N.
    Nishino, T.
    Takashi, M.
    Tsubota, A.
    Kato, K.
    Sugiura, N.
    Tawada, A.
    Wu, S.
    Tanaka, T.
    Nakamoto, S.
    Mikata, R.
    Tada, M.
    Chiba, T.
    Kurihara, T.
    Arai, M.
    Fujiwara, K.
    Kanai, F.
    Yokosuka, O.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (07) : E292 - E297
  • [5] RESPONSE GUIDED THERAPY BY PEGINTERFERON A2B PLUS RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 2
    Yamaguchi, Y.
    Tamori, A.
    Tanaka, Y.
    Iwai, S.
    Kobayashi, S.
    Fujii, H.
    Morikawa, H.
    Hagihara, A.
    Enomoto, M.
    Kawada, N.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S462 - S462
  • [6] RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS INFECTED WITH HCV GENOTYPE 1: INTERIM RESULTS FROM THE TriCo STUDY
    Ferenci, P.
    Flisiak, R.
    Caruntu, F. A.
    Lengyel, G.
    Hohmann, M.
    Bakalos, G.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S453 - S454
  • [7] EFFECT OF TIME TO RESPONSE ON VIRAL BREAKTHROUGH AND RELAPSE RATES IN PATIENTS INFECTED WITH HCV GENOTYPE 1 AND TREATED WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN
    Shiffman, Mitchell L.
    Hamzeh, Fayez M.
    Chung, Raymond T.
    HEPATOLOGY, 2008, 48 (04) : 862A - 862A
  • [8] Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
    Sarrazin, Christoph
    Shiffman, Mitchell L.
    Hadziyannis, Stephanos J.
    Lin, Amy
    Colucci, Giuseppe
    Ishida, Hiroshi
    Zeuzem, Stefan
    JOURNAL OF HEPATOLOGY, 2010, 52 (06) : 832 - 838
  • [9] SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV
    Sulkowski, M.
    Bourliere, M.
    Bronowicki, J. -P.
    Streinu-Cercel, A.
    Preotescu, L.
    Asselah, T.
    Pawlotsky, J. -M.
    Shafran, S.
    Pol, S.
    Caruntu, F. A.
    Mauss, S.
    Larrey, D.
    Haefner, C.
    Datsenko, Y.
    Stern, J.
    Kubiak, R.
    Steinmann, G.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S462 - S463
  • [10] CLINICAL RELEVANCE OF MINIMAL RESIDUAL VIREMIA DETECTED WITH THE ABBOTT REALTIME HCV ASSAY FOR RESPONSE-GUIDED THERAPY WITH PEG-INTERFERON-α/RIBAVIRIN IN PATIENTS WITH HEPATITIS-C-VIRUS GENOTYPE 1 INFECTION
    Vermehren, J.
    Susser, S.
    Perner, D.
    Fueller, C.
    Zeuzem, S.
    Sarrazin, C.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S461 - S461
12345